InterCure moves towards NASDAQ listing Trading is expected to begin in the last week of July
TORONTO, July 19, 2021 (GLOBE NEWSWIRE) – InterCure Ltd.. (TSX: INCR.U, TASE: INCR) (dba Canndoc) (the “Company“) is pleased to announce that following its confidential filing with the United States Securities and Exchange Commission (the”SECOND“) of its 20F registration statement on April 20, 2021, it filed its 20F registration statement under the Securities Exchange Act of 1933 and the F-1 registration statement under the Securities Act of 1933. The complete statements are available on the Company’s SEDAR profile as well as on EDGAR:
Listing on NASDAQ is subject to satisfaction of all applicable listing and regulatory requirements, including registration of common shares with the SEC, requirements and approvals of the NASDAQ. Upon receipt of all required approvals, the Company will issue a press release announcing its first trading day on NASDAQ.
About InterCure (dba Canndoc)
InterCure (dba Canndoc) (TSX: INCR.U, TASE: INCR) is Israel’s leading, fastest growing and most profitable cannabis company. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer medical cannabis products certified to Good Manufacturing Practices (GMP) and pharmaceutical grade. InterCure leverages its market-leading distribution network, best-in-class international partnerships, and a vertically integrated, high-margin “seed-to-sell” model to become the world’s most profitable cannabis company outside of the world. ‘North America.
InterCure is listed on the Toronto Stock Exchange under the symbol INCR.U and trades on the Tel Aviv Stock Exchange under the symbol INCR.TA. Subject to satisfaction of the NASDAQ listing conditions, InterCure common stock is expected to begin trading on NASDAQ during the last week of July 2021 and will trade under the symbol “INCR”.
For more information visit: http://www.intercure.co
This press release may contain forward-looking information within the meaning of applicable securities laws, which reflects InterCure’s current expectations regarding future events. The words “will”, “expects”, “intention”, “plans” and similar expressions are often intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Specific forward-looking information contained in this press release includes, but is not limited to: listing of Common Shares on NASDAQ. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the control of InterCure, which could cause actual results and events to differ. substantially from those disclosed or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: changes in economic, business and general political conditions. InterCure assumes no obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Amos Cohen, Chief Financial Officer